A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI's Landmark FDA Approval For FSGS [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
Travere Therapeutics (TVTX) is back in focus after the U.S. FDA approved FILSPARI as the first and only therapy for focal segmental glomerulosclerosis in certain adults and children, thereby expanding the drug's rare kidney disease footprint. See our latest analysis for Travere Therapeutics. The FDA approval headlines have coincided with sharp share price momentum, with a 7 day share price return of 29.3% and a 30 day share price return of 46.1%. This has contributed to a 1 year total shareholder return of 181.1% and an 88.3% total shareholder return over three years. If this kind of rare disease catalyst has caught your attention, it could be a good time to broaden your watchlist with 35 healthcare AI stocks With Travere now carrying a full FDA approval for FILSPARI in FSGS and the share price already up strongly, the key question for investors is whether TVTX still trades at a discount or if the market is already pricing in future growth. Most Popular Narrative: 3.6% Unde
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- How The Travere Therapeutics (TVTX) Story Is Shifting After FSGS Approval And Split Analyst Views [Yahoo! Finance]Yahoo! Finance
- Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Travere Therapeutics (TVTX) was upgraded by Piper Sandler from "neutral" to "overweight". They now have a $49.00 price target on the stock.MarketBeat
- Travere Therapeutics (TVTX) had its price target raised by Canaccord Genuity Group Inc. from $47.00 to $56.00. They now have a "buy" rating on the stock.MarketBeat
TVTX
Earnings
- 2/19/26 - Beat
TVTX
Sec Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- TVTX's page on the SEC website